{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:08:53Z","timestamp":1790752133679,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40263-021-00864-3","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T19:04:30Z","timestamp":1634324670000},"page":"1153-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-7016","authenticated-orcid":false,"given":"Joshua T.","family":"Kantrowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"issue":"5","key":"864_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40263-017-0428-x","volume":"31","author":"JT Kantrowitz","year":"2017","unstructured":"Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017;31(5):373\u201388.","journal-title":"CNS Drugs"},{"issue":"1","key":"864_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-021-00145-4","volume":"7","author":"GP Strauss","year":"2021","unstructured":"Strauss GP, Bartolomeo LA, Harvey PD. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr. 2021;7(1):16.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"864_CR3","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1192\/j.eurpsy.2021.11","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1):e23.","journal-title":"Eur Psychiatry"},{"key":"864_CR4","first-page":"1","volume":"16","author":"JT Kantrowitz","year":"2021","unstructured":"Kantrowitz JT. How do we address treating the negative symptoms of schizophrenia pharmacologically? Expert Opin Pharmacother. 2021;16:1\u20133.","journal-title":"Expert Opin Pharmacother"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbi004","volume":"31","author":"MM Kurtz","year":"2005","unstructured":"Kurtz MM, Moberg JP, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31:167\u201374.","journal-title":"Schizophr Bull"},{"issue":"2","key":"864_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","volume":"58","author":"B Kirkpatrick","year":"2001","unstructured":"Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165\u201371.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"864_CR7","first-page":"19","volume":"42","author":"RS Keefe","year":"2016","unstructured":"Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, et al. Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in schizophrenia. Schizophr Bull. 2016;42(1):19\u201333.","journal-title":"Schizophr Bull"},{"issue":"5","key":"864_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamapsychiatry.2020.4614","volume":"78","author":"A Mucci","year":"2021","unstructured":"Mucci A, Galderisi S, Gibertoni D, Rossi A, Rocca P, Bertolino A, et al. Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses. JAMA Psychiat. 2021;78(5):550\u20139.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"864_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW, Podhorna J, Groschl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191\u2013201.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"864_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","volume":"40","author":"WW Shen","year":"1999","unstructured":"Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40(6):407\u201314.","journal-title":"Compr Psychiatry"},{"key":"864_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.schres.2020.11.022","volume":"229","author":"RE Lawrence","year":"2021","unstructured":"Lawrence RE, Appelbaum PS, Lieberman JA. A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise. Schizophr Res. 2021;229:122\u201331.","journal-title":"Schizophr Res"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"204512531987003","DOI":"10.1177\/2045125319870033","volume":"9","author":"M Taylor","year":"2019","unstructured":"Taylor M, Jauhar S. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Therap Adv Psychopharmacol. 2019;9:2045125319870033.","journal-title":"Therap Adv Psychopharmacol"},{"issue":"6","key":"864_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","volume":"39","author":"E Jaaskelainen","year":"2013","unstructured":"Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296\u2013306.","journal-title":"Schizophr Bull"},{"key":"864_CR14","first-page":"1","volume":"2","author":"JT Kantrowitz","year":"2021","unstructured":"Kantrowitz JT. Additional perspective on cariprazine and negative symptoms. Exp Opin Pharmacotherapy. 2021;2:1\u20132.","journal-title":"Exp Opin Pharmacotherapy."},{"issue":"1","key":"864_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/00325481.2019.1701823","volume":"132","author":"AM Meftah","year":"2020","unstructured":"Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. Postgrad Med. 2020;132(1):80\u201390.","journal-title":"Postgrad Med"},{"issue":"10202","key":"864_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"12","key":"864_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"issue":"4194","key":"864_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1126\/science.1145194","volume":"188","author":"P Seeman","year":"1975","unstructured":"Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188(4194):1217\u20139.","journal-title":"Science"},{"issue":"4783","key":"864_CR19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1126\/science.2878495","volume":"234","author":"DF Wong","year":"1986","unstructured":"Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986;234(4783):1558\u201363.","journal-title":"Science"},{"issue":"11","key":"864_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","volume":"50","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873\u201383.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"864_CR21","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3390\/ijms22094467","volume":"22","author":"FV Gomes","year":"2021","unstructured":"Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci. 2021;22(9):4467.","journal-title":"Int J Mol Sci"},{"key":"864_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fphar.2020.01005","volume":"11","author":"R Kozak","year":"2020","unstructured":"Kozak R, Kiss T, Dlugolenski K, Johnson DE, Gorczyca RR, Kuszpit K, et al. Characterization of PF-6142, a novel, non-catecholamine dopamine receptor D1 agonist, in murine and nonhuman primate models of dopaminergic activation. Front Pharmacol. 2020;11:1005.","journal-title":"Front Pharmacol"},{"issue":"11","key":"864_CR23","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41386-019-0355-2","volume":"44","author":"I Bitter","year":"2019","unstructured":"Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019;44(11):1917\u201324.","journal-title":"Neuropsychopharmacology"},{"key":"864_CR24","first-page":"4","volume":"5","author":"N de la Garrigue","year":"2020","unstructured":"de la Garrigue N, Glasser J, Sehatpour P, Iosifescu DV, Dias E, Carlson M, et al. Grant report on d-serine augmentation of neuroplasticity-based auditory learning in schizophrenia (dagger). J Psychiatr Brain Sci. 2020;5:4.","journal-title":"J Psychiatr Brain Sci"},{"issue":"12","key":"864_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174(12):1195\u2013202.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"864_CR26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40263-020-00752-2","volume":"34","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz JT. Targeting serotonin 5-HT2A receptors to better treat schizophrenia: rationale and current approaches. CNS Drugs. 2020;34(9):947\u201359.","journal-title":"CNS Drugs"},{"issue":"11","key":"864_CR27","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41386-020-0706-z","volume":"45","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology. 2020;45(11):1842\u201350.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"864_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717\u201326.","journal-title":"N Engl J Med"},{"issue":"16","key":"864_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506.","journal-title":"N Engl J Med"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161\u201380.","journal-title":"Pharmacol Ther"},{"key":"864_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neubiorev.2020.09.028","volume":"120","author":"S Dodd","year":"2021","unstructured":"Dodd S, Puri BK, Maes M, Bortolasci CC, Morris G, et al. Trace amine-associated receptor 1 (TAAR1): a new drug target for psychiatry? Neurosci Biobehav Rev. 2021;120:537\u201341.","journal-title":"Neurosci Biobehav Rev"},{"key":"864_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnins.2016.00148","volume":"10","author":"Y Pei","year":"2016","unstructured":"Pei Y, Asif-Malik A, Canales JJ. Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry, and clinical implications. Front Neurosci. 2016;10:148.","journal-title":"Front Neurosci"},{"issue":"987","key":"864_CR33","first-page":"987","volume":"8","author":"G Rutigliano","year":"2017","unstructured":"Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol. 2017;8(987):987.","journal-title":"Front Pharmacol"},{"issue":"6","key":"864_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14728222.2018.1480723","volume":"22","author":"MD Schwartz","year":"2018","unstructured":"Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018;22(6):513\u201326.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"864_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1471-4892(02)00028-0","volume":"3","author":"TA Branchek","year":"2003","unstructured":"Branchek TA, Blackburn TP. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol. 2003;3(1):90\u20137.","journal-title":"Curr Opin Pharmacol"},{"key":"864_CR36","first-page":"2","volume":"2","author":"PC Nair","year":"2021","unstructured":"Nair PC, Miners JO, McKinnon RA, Langmead CJ, Gregory KJ, Copolov D, et al. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol Psychiatry. 2021;2:2.","journal-title":"Mol Psychiatry"},{"issue":"7871","key":"864_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0140-6736(74)91390-7","volume":"2","author":"AA Boulton","year":"1974","unstructured":"Boulton AA. Letter: amines and theories in psychiatry. Lancet. 1974;2(7871):52\u20133.","journal-title":"Lancet"},{"issue":"16","key":"864_CR38","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"B Borowsky","year":"2001","unstructured":"Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A. 2001;98(16):8966\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"864_CR39","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181\u20138.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"864_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2007.06.007","volume":"116","author":"DK Grandy","year":"2007","unstructured":"Grandy DK. Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther. 2007;116(3):355\u201390.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"864_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.106.112532","volume":"320","author":"DB Wainscott","year":"2007","unstructured":"Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, et al. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. J Pharmacol Exp Ther. 2007;320(1):475\u201385.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"864_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1017\/S0317167100023313","volume":"7","author":"AA Boulton","year":"1980","unstructured":"Boulton AA. Trace amines and mental disorders. Can J Neurol Sci. 1980;7(3):261\u20133.","journal-title":"Can J Neurol Sci"},{"issue":"7950","key":"864_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(76)90156-2","volume":"1","author":"M Sandler","year":"1976","unstructured":"Sandler M, Reynolds GP. Does phenylethylamine cause schizophrenia? Lancet. 1976;1(7950):70\u20131.","journal-title":"Lancet"},{"issue":"4417","key":"864_CR44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1126\/science.504988","volume":"206","author":"SG Potkin","year":"1979","unstructured":"Potkin SG, Karoum F, Chuang LW, Cannon-Spoor HE, Phillips I, Wyatt RJ. Phenylethylamine in paranoid chronic schizophrenia. Science. 1979;206(4417):470\u20131.","journal-title":"Science"},{"issue":"4","key":"864_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/070674379504000417","volume":"40","author":"S Shirkande","year":"1995","unstructured":"Shirkande S, O\u2019Reilly R, Davis B, Durden D, Malcom D. Plasma phenylethylamine levels of schizophrenic patients. Can J Psychiatry. 1995;40(4):221.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"864_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10571-019-00743-y","volume":"40","author":"G Rutigliano","year":"2020","unstructured":"Rutigliano G, Zucchi R. Molecular variants in human trace amine-associated receptors and their implications in mental and metabolic disorders. Cell Mol Neurobiol. 2020;40(2):239\u201355.","journal-title":"Cell Mol Neurobiol"},{"issue":"750","key":"864_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2014.11.047","volume":"5","author":"V Alexandrov","year":"2015","unstructured":"Alexandrov V, Brunner D, Hanania T, Leahy E. High-throughput analysis of behavior for drug discovery. Eur J Pharmacol. 2015;5(750):82\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"864_CR48","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","volume":"324","author":"L Lindemann","year":"2008","unstructured":"Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324(3):948\u201356.","journal-title":"J Pharmacol Exp Ther"},{"issue":"47","key":"864_CR49","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","volume":"106","author":"A Bradaia","year":"2009","unstructured":"Bradaia A, Trube G, Stalder H, Norcross RD, Ozmen L, Wettstein JG, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009;106(47):20081\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"864_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neuropharm.2014.02.007","volume":"81","author":"D Leo","year":"2014","unstructured":"Leo D, Mus L, Espinoza S, Hoener MC, Sotnikova TD, Gainetdinov RR. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacol. 2014;81:283\u201391.","journal-title":"Neuropharmacol"},{"issue":"7","key":"864_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/FBP.0000000000000330","volume":"28","author":"JN Siemian","year":"2017","unstructured":"Siemian JN, Zhang Y, Li JX. Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats. Behav Pharmacol. 2017;28(7):590\u20133.","journal-title":"Behav Pharmacol"},{"issue":"3","key":"864_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(96)00300-7","volume":"308","author":"RR Gainetdinov","year":"1996","unstructured":"Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol. 1996;308(3):261\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"864_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1124\/mol.111.073304","volume":"80","author":"S Espinoza","year":"2011","unstructured":"Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol. 2011;80(3):416\u201325.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"864_CR54","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","volume":"25","author":"A Harmeier","year":"2015","unstructured":"Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, et al. Trace amine-associated receptor 1 activation silences GSK3beta signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25(11):2049\u201361.","journal-title":"Eur Neuropsychopharmacol"},{"key":"864_CR55","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.02.010","volume":"93","author":"S Espinoza","year":"2015","unstructured":"Espinoza S, Ghisi V, Emanuele M, Leo D, Sukhanov I, Sotnikova TD, et al. Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. Neuropharmacol. 2015;93:308\u201313.","journal-title":"Neuropharmacol"},{"issue":"7","key":"864_CR56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1601-183X.2006.00292.x","volume":"6","author":"TD Wolinsky","year":"2007","unstructured":"Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, et al. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007;6(7):628\u201339.","journal-title":"Genes Brain Behav"},{"issue":"7","key":"864_CR57","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","volume":"27","author":"S Kapur","year":"2003","unstructured":"Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081\u201390.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"864_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/sj.npp.1301071","volume":"32","author":"JD Urban","year":"2007","unstructured":"Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1):67\u201377.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"864_CR59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamapsychiatry.2019.4265","volume":"77","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz JT. The potential role of lumateperone-something borrowed? something new? JAMA Psychiat. 2020;77(4):343\u20134.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"864_CR60","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","volume":"44","author":"KE Vanover","year":"2019","unstructured":"Vanover KE, Davis RE, Zhou Y, Ye W, Brasic JR, Gapasin L, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598\u2013605.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"864_CR61","doi-asserted-by":"publisher","first-page":"13901","DOI":"10.1038\/s41598-017-14472-z","volume":"7","author":"A Asif-Malik","year":"2017","unstructured":"Asif-Malik A, Hoener MC, Canales JJ. Interaction between the trace amine-associated receptor 1 and the dopamine D2 receptor controls cocaine\u2019s neurochemical actions. Sci Rep. 2017;7(1):13901.","journal-title":"Sci Rep"},{"issue":"12","key":"864_CR62","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41386-018-0017-9","volume":"43","author":"JF Liu","year":"2018","unstructured":"Liu JF, Seaman R Jr, Siemian JN, Bhimani R, Johnson B, Zhang Y, et al. Role of trace amine-associated receptor 1 in nicotine\u2019s behavioral and neurochemical effects. Neuropsychopharmacology. 2018;43(12):2435\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"864_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2018.00329","volume":"9","author":"I Sukhanov","year":"2018","unstructured":"Sukhanov I, Dorofeikova M, Dolgorukova A, Dorotenko A, Gainetdinov RR. Trace amine-associated receptor 1 modulates the locomotor and sensitization effects of nicotine. Front Pharmacol. 2018;9:329.","journal-title":"Front Pharmacol"},{"issue":"1","key":"864_CR64","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41598-017-18526-0","volume":"8","author":"JM Gemechu","year":"2018","unstructured":"Gemechu JM, Sharma A, Yu D, Xie Y, Merkel OM, Moszczynska A. Characterization of dopaminergic system in the striatum of young adult Park2(-\/-) knockout rats. Sci Rep. 2018;8(1):1517.","journal-title":"Sci Rep"},{"key":"864_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.neuropharm.2014.06.011","volume":"85","author":"IE Cisneros","year":"2014","unstructured":"Cisneros IE, Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacol. 2014;85:499\u2013507.","journal-title":"Neuropharmacol"},{"issue":"5","key":"864_CR66","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"FG Revel","year":"2013","unstructured":"Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18(5):543\u201356.","journal-title":"Mol Psychiatry"},{"issue":"20","key":"864_CR67","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011;108(20):8485\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"864_CR68","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/npp.2015.65","volume":"40","author":"S Espinoza","year":"2015","unstructured":"Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, et al. TAAR1 modulates cortical glutamate NMDA receptor function. Neuropsychopharmacology. 2015;40(9):2217\u201327.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"864_CR69","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"A Egerton","year":"2018","unstructured":"Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23(11):2145\u201355.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"864_CR70","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbv151","volume":"42","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42(3):744\u201352.","journal-title":"Schizophr Bull"},{"issue":"10","key":"864_CR71","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","volume":"5","author":"S Jauhar","year":"2018","unstructured":"Jauhar S, McCutcheon R, Borgan F, Veronese M, Nour M, Pepper F, et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry. 2018;5(10):816\u201323.","journal-title":"Lancet Psychiatry"},{"key":"864_CR72","first-page":"2","volume":"2","author":"K Merritt","year":"2021","unstructured":"Merritt K, McGuire PK, Egerton A, Investigators HMiS, Aleman A, Block W, , et al. Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data. JAMA Psychiat. 2021;2:2.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"864_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","volume":"23","author":"M Kokkinou","year":"2018","unstructured":"Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23(1):59\u201369.","journal-title":"Mol Psychiatry"},{"key":"864_CR74","first-page":"2","volume":"2","author":"M Kokkinou","year":"2020","unstructured":"Kokkinou M, Irvine EE, Bonsall DR, Natesan S, Wells LA, Smith M, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2020;2:2.","journal-title":"Mol Psychiatry"},{"issue":"14","key":"864_CR75","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","volume":"97","author":"A Abi-Dargham","year":"2000","unstructured":"Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97(14):8104\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"864_CR76","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fphar.2019.00470","volume":"10","author":"AA Aleksandrov","year":"2019","unstructured":"Aleksandrov AA, Knyazeva VM, Volnova AB, Dmitrieva ES, Polyakova NV, Gainetdinov RR. Trace amine-associated receptor 1 agonist modulates mismatch negativity-like responses in mice. Front Pharmacol. 2019;10:470.","journal-title":"Front Pharmacol"},{"key":"864_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2018.02.003","volume":"207","author":"JT Kantrowitz","year":"2019","unstructured":"Kantrowitz JT. N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. Schizophr Res. 2019;207:70\u20139.","journal-title":"Schizophr Res"},{"issue":"7","key":"864_CR78","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.bpsc.2018.02.002","volume":"3","author":"JT Kantrowitz","year":"2018","unstructured":"Kantrowitz JT, Swerdlow NR, Dunn W, Vinogradov S. Auditory system target engagement during plasticity-based interventions in schizophrenia: a focus on modulation of N-methyl-D-aspartate-type glutamate receptor function. Biol Psychiatry Cognit Neurosci Neuroimaging. 2018;3(7):581\u201390.","journal-title":"Biol Psychiatry Cognit Neurosci. Neuroimaging."},{"key":"864_CR79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.schres.2017.05.031","volume":"191","author":"LM Greenwood","year":"2018","unstructured":"Greenwood LM, Leung S, Michie PT, Green A, Nathan PJ, Fitzgerald P, et al. The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophr Res. 2018;191:61\u20139.","journal-title":"Schizophr Res"},{"issue":"Pt 12","key":"864_CR80","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1093\/brain\/aww262","volume":"139","author":"JT Kantrowitz","year":"2016","unstructured":"Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, et al. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain. 2016;139(Pt 12):3281\u201395.","journal-title":"Brain"},{"key":"864_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2017.02.027","volume":"191","author":"JT Kantrowitz","year":"2018","unstructured":"Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res. 2018;191:70\u20139.","journal-title":"Schizophr Res"},{"issue":"9","key":"864_CR82","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","volume":"33","author":"S Lavoie","year":"2008","unstructured":"Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33(9):2187\u201399.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"864_CR83","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S1461145799001595","volume":"2","author":"D Umbricht","year":"1999","unstructured":"Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmcol. 1999;2(4):299\u2013304.","journal-title":"Int J Neuropsychopharmcol"},{"key":"864_CR84","first-page":"2","volume":"2","author":"P Sehatpour","year":"2021","unstructured":"Sehatpour P, Javitt DC, De Baun HM, Carlson M, Margolin DH, Brice N, et al. Mismatch negativity as an index of target engagement for excitation\/inhibition-based treatment development: A double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Res Square (preprint). 2021;2:2.","journal-title":"Res Square (preprint)."},{"key":"864_CR85","first-page":"2","volume":"2","author":"P Sehatpour","year":"2021","unstructured":"Sehatpour P, Javitt DC, De Baun HM, Carlson M, Belobordova A, Margolin DH, et al. Mismatch negativity as an index of target engagement for excitation\/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacol. 2021;2:2.","journal-title":"Neuropsychopharmacol"},{"issue":"1","key":"864_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41398-020-01119-3","volume":"11","author":"O Razakarivony","year":"2021","unstructured":"Razakarivony O, Newman-Tancredi A, Zimmer L. Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges. Transl Psychiatry. 2021;11(1):22.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"864_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1\u201314.","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"864_CR88","first-page":"11","volume":"23","author":"D De Gregorio","year":"2016","unstructured":"De Gregorio D, Comai S, Posa L, Gobbi G. d-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci. 2016;23(17):11.","journal-title":"Int J Mol Sci"},{"key":"864_CR89","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","volume":"99","author":"A Rickli","year":"2015","unstructured":"Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacol. 2015;99:546\u201353.","journal-title":"Neuropharmacol"},{"issue":"8","key":"864_CR90","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327\u201337.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"864_CR91","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1017\/S1092852920002357","volume":"26","author":"CU Correll","year":"2021","unstructured":"Correll CU, Koblan KS, Hopkins SC, Kent J, Cheng H, Goldman R, et al. Safety and effectiveness of sep-363856 in schizophrenia: results of a 6-month, Open-Label Extension Study. CNS Spectr. 2021;26(2):148\u20139.","journal-title":"CNS Spectr"},{"issue":"2","key":"864_CR92","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"15","key":"864_CR93","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/WNR.0000000000001313","volume":"30","author":"AA Aleksandrov","year":"2019","unstructured":"Aleksandrov AA, Dmitrieva ES, Volnova AB, Knyazeva VM, Gainetdinov RR, Polyakova NV. Effect of trace amine-associated receptor 1 agonist RO5263397 on sensory gating in mice. NeuroReport. 2019;30(15):1004\u20137.","journal-title":"NeuroReport"},{"issue":"2","key":"864_CR94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10571-019-00757-6","volume":"40","author":"A Dorotenko","year":"2020","unstructured":"Dorotenko A, Tur M, Dolgorukova A, Bortnikov N, Belozertseva IV, Zvartau EE, et al. The action of TAAR1 agonist RO5263397 on executive functions in rats. Cell Mol Neurobiol. 2020;40(2):215\u201328.","journal-title":"Cell Mol Neurobiol"},{"key":"864_CR95","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fphar.2018.00645","volume":"9","author":"S Espinoza","year":"2018","unstructured":"Espinoza S, Leo D, Sotnikova TD, Shahid M, Kaariainen TM, Gainetdinov RR. Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397. Front Pharmacol. 2018;9:645.","journal-title":"Front Pharmacol"},{"issue":"7","key":"864_CR96","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/npp.2016.233","volume":"42","author":"A Ferragud","year":"2017","unstructured":"Ferragud A, Howell AD, Moore CF, Ta TL, Hoener MC, Sabino V, et al. The trace amine-associated receptor 1 agonist RO5256390 blocks compulsive, Binge-like eating in rats. Neuropsychopharmacology. 2017;42(7):1458\u201370.","journal-title":"Neuropsychopharmacology"},{"key":"864_CR97","doi-asserted-by":"publisher","first-page":"112641","DOI":"10.1016\/j.bbr.2020.112641","volume":"390","author":"R Wu","year":"2020","unstructured":"Wu R, Liu J, Wang K, Huang Y, Zhang Y, Li JX. Effects of a trace amine-associated receptor 1 agonist RO 5263397 on ethanol-induced behavioral sensitization. Behav Brain Res. 2020;390:112641.","journal-title":"Behav Brain Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00864-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T06:08:58Z","timestamp":1706249338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":97,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00864-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"20 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received specifically for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Dr. Kantrowitz reports having received consulting payments within the last 24 months from Alphasights, Charles River Associates, Medscape, Putnam, techspert.io, Third Bridge, MEDACorp, Parexel, GroupH, ECRI Institute, ExpertConnect, Parexel, Schlesinger Group, CelloHealth, Acsel Health, Antheum, Strafluence, Guidepoint, L.E.K., SmartAnalyst, and System Analytic. He has served on the MedinCell Psychiatry and the Karuna Mechanism of Action (MOA) Advisory Boards. He has conducted clinical research supported by the NIMH, Sunovion, Roche, Alkermes, Cerevance, Corcept, Takeda, Taisho, Boehringer Ingelheim, NeuroRX, and Teva within the last 24 months. He owns a small number of shares of common stock from GSK.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Kantrowitz was responsible for all aspects of the drafting and revision of the review, and agrees to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author's contribution"}}]}}